Showing posts with label natural progesterone. Show all posts
Showing posts with label natural progesterone. Show all posts

Sunday, April 30, 2017

In case you missed it: Here are the top 5 posts this month.



Ethicon STRATAFIX™ Spiral Plus Devices transforms wound closure experience for surgeons.

Ethicon has launched Stratafix Spiral PDS Plus and Stratafix Spiral Monocryl Plus Knotless Tissue Control Devices that provides a unique edge over traditional suturing.
Stratafix sutures enables more strength, consistency, security and efficiency over its predecessors because the surgeon can manage tension and control tissue approximation with each pass. It also eliminates the need to tie knots.


Mayo Clinic Tampon Test for detecting Endometrial Cancer at early stage.

There is no standard screening test to identify endometrial cancer, hence it is often detected late when the disease has already advanced.
Mayo clinic expert Jamie N. Bakkum-Gamez, M.D. and her team are in the process of developing a simple screening test that can be done at home using a tampon. It is based on the concept of detecting tumor DNA hypermethylation in vaginal pool DNA picked up by ordinary tampon.

At last, a no surgery, no knife, noninvasive treatment for uterine fibroid receives European approval.

Mirabilis Medical, a Seattle based company received CE Mark authorization for marketing of the Mirabilis System for treatment of uterine fibroids throughout the European Union.  It also announced that it had received a green signal from US-FDA to begin its clinical studies in US.
The Mirabilis system is a High-Intensity Focused Ultrasound (HIFU) system consists of an ultrasound system that has two parts: the imaging part and the therapy part.

Synthetic progestogens, but not natural progesterone, lowers miscarriage risk among women with unexplained RPL: Systematic review and meta-analysis.

Women taking progestogens have a 28% lower risk of miscarriage (RR 0.72; 95% CI 0.53-0.97).  and 7% higher chances of live births as compared to women who did not receive any supplementation. (RR 1.07, 95% CI 1.02–1.15).
The Meta-analysis included 10 trials comprising a total of 1,586 women with history of recurrent miscarriage.

Sperms used as vehicle for targeted drug delivery in gynecological cancers.

Sperms are not just for baby-making anymore, but can be used as cargo agents for delivering drugs inside the body.
Getting the chemotherapeutic agent to only kill the tumor cells without affecting the normal cells is a dream come true in area of cancer therapeutics because of Targeted drug delivery systems(TDDS).
Targeted drug delivery systems using polymeric nanoparticles have opened up new avenues in cancer chemotherapy.  Liposomes have shown to be effective among an array of nano- and microcarriers but have the drawback of dilution by body fluids, decreased penetration and uptake by non-target tissues.


Tuesday, April 18, 2017

Synthetic progestogens, but not natural progesterone, lowers miscarriage risk among women with unexplained RPL: Systematic review and meta-analysis.


Courtesy: Makena
Supplementation with progesterone reduces the risk of early pregnancy loss in women with unexplained earlier recurrent losses according to a Systematic review and meta-analysis published in Journal of Fertility and Sterility.

Women taking progestogens have a 28% lower risk of miscarriage (RR 0.72; 95% CI 0.53-0.97).  and 7% higher chances of live births as compared to women who did not receive any supplementation. (RR 1.07, 95% CI 1.02–1.15).

The Meta-analysis included 10 trials comprising a total of 1,586 women with history of recurrent miscarriage.

Two RCTs used natural progesterone while the rest 8 used progestins like medroxyprogesterone, cyclopentylenol ether of progesterone, dydrogesterone, or 17-hydroxyprogesterone caproate.

Pooled data did not show statically significant difference for secondary outcome of the studies like preterm births, fetal genital malformations and neonatal mortality.

Interestingly, vaginal progesterone and natural progesterone did not much effect the miscarriage rate while oral, intramuscular and synthetic form significantly lowered the miscarriage rate.

Intramuscular 17-alpha hydroxyprogesterone caproate weekly and oral dydrogesterone were both associated with significant reduction in miscarriage risk.

The authors conclude that because of limitations RCTs included in this meta-analysis, a recommendation regarding type and route of progesterone administrations are not possible to make.
Till we have more data from head to head analysis about route and type of progesterone, synthetic progestogens supplementation should be started in women with RPL as soon as pregnancy is confirmed.

Recurrent pregnancy loss (RPL) occurs in 5% of women. Many hematological, anatomic, hormonal, immune and genetic defect have been attributed in its causation but in most patients extensive evaluation is not able to pinpoint a cause.